|Synonym :||Belviq, Apd 356, (1R)-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine|
|Assay :||99% min|
|Boiling point :||288.125°C at 760 mmHg|
|Quality Standards :||USP|
|Appearance :||White to almost white crystalline powder|
Lorcaserin is a prescription medication used to help adults who are obese or who are overweight and have weight-related medical problems to lose weight and keep from gaining back that weight. Lorcaserin must be used along with a reduced calorie diet and an exercise plan.
Description of Lorcaserin:
|1||Lorcaserin is used long term for weight loss in those who are obese.|
|2||Lorcaserin is a prescription medication used to help adults who are obese or who are overweight and have weight-related medical problems to lose weight and keep from gaining back that weight. Lorcaserin must be used along with a reduced calorie diet and an exercise plan.|
|3||Lorcaserin, currently marketed under the trade name Belviq and previously Lorqess during development, is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic.|
|4||Lorcaserin is a selective 5-HT2C receptor agonist, and in vitro testing of the drug showed reasonable selectivity for 5-HT2C over other related targets.5-HT2C receptors are located almost exclusively in the brain, and can be found in the choroid plexus, cortex, hippocampus, cerebellum, amygdala, thalamus, and hypothalamus. The activation of 5-HT2C receptors in the hypothalamus is supposed to activateproopiomelanocortin (POMC) production and consequently promote weight loss through satiety.This hypothesis is supported by clinical trials and other studies.|
Dosage of Lorcaserin:
Lorcaserin is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in obese adults (a BMI of 30 kg/m2 or greater) or in overweight patients (BMI of 27 kg/m2 or greater) with at least one weight-related comorbid condition, such as hypertension, type-2 diabetes, or dyslipidemia.
The recommended dose is 10 mg orally twice daily with or without food. If patients do not achieve a 5% reduction in weight by week 12, they should stop taking lorcaserin because it is unlikely that they will achieve any weight loss with the medication.
Lorcaserin may be used in patients with mild-to-moderate hepatic impairment who require no dose adjustments; however, caution is recommended for patients with severe hepatic impairment, because the effects in this population have not been studied.Although lorcaserin may be used in patients with mild renal impairment, caution is advised for those with moderate renal impairment. The use of lorcaserin in patients with severe renal impairment or end-stage renal failure is not recommended.
Lorcaserin is contraindicated in pregnant women, and it is listed as a Pregnancy Category X medication. It was found to offer no known benefit in pregnant women, because it promotes weight loss.There are no data supporting the use of the medication in nursing mothers.